A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)
by on Friday, August 31st, 2012 | No Comments
Condition: Relapsed or Refractory Diffuse Large B Cell Lymphoma
Intervention: Drug: 131I-rituximab
Sponsors: Korea Cancer Center Hospital; Korea Cancer Center Hospital
Active, not recruiting – verified August 2012
View post: A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)